Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $82.00. They now have a "buy" rating on the stock.
LowReport
Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $82.00. They now have a "buy" rating on the stock.
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas [Yahoo! Finance]
LowReport
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: